Wednesday, April 28, 2021 1:07:19 PM
We're very excited to have the experience of Greg McKee leading Tryp Therapeutics.
His background leading publicly traded pharmaceutical companies, as well as his experience in biotech and drug development, will be incredibly valuable in our next phase of growth.
There are currently no approved drugs and only limited treatment options for patients with rare over-eating disorders.
That's why we are focusing on developing our TRP-8802 novel formulation to better address these rare and debilitating disorders.
$TRYP $TRYPF
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM